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Abstract
Purpose of Review Acute myeloid leukaemia (AML) is a heterogeneous malignancy for which treatment options remain sub-
optimal. It is clear that a greater understanding of the biology of the AML niche will enable new therapeutic strategies to be
developed in order to improve treatment outcomes for patients.
Recent Findings Recent evidence has highlighted the importance of the bone marrowmicroenvironment in protecting leukaemia
cells, and in particular leukaemic stem cells from chemotherapy-induced cell death. This includes mesenchymal stem cells
supporting growth and preventing apoptosis, and altered action and secretion profiles of other niche components including
adipocytes, endothelial cells and T cells.
Summary Here, we provide a detailed overview of the current understanding of the AML bone marrow microenvironment.
Clinical trials of agents that mobilise leukaemic stem cells from the bone marrow are currently ongoing and show early promise.
Future challenges will involve combining these novel therapies targeted at the AML niche with conventional chemotherapy
treatment.
Keywords AML . Niche . Microenvironment . Bone marrow . Stromal cells . CXCR4 . CXCL12 . Acute myeloid leukaemia .
DNMT3A . Leukaemic stem cell . Blast . Mesenchymal cells . Tcells . Stroma
Introduction
Acute myeloid leukaemia (AML) remains a therapeutic chal-
lenge due to its heterogeneity. It is characterized by uncon-
trolled expansion of myeloid progenitors in the bone marrow
(BM) and the peripheral blood. Approximately 80% of pa-
tients undergo complete remission, according to the AML10
study. However, the long-term disease-free survival at 6 years
was shown to be only 40%, mainly due to relapse risk which
was estimated as high as 50% [1]. Patients with AML have a
10% 5-year overall survival from first relapse. Most patients
do not achieve a second remission and, as a result, do not have
an opportunity for a potential cure [2]. Relapse after initial
response to chemotherapy remains a challenge. New thera-
peutic strategies are needed, focusing on the elimination of
the remnant chemo-resistant leukaemic cells in the bone mar-
row, thus preventing relapses.
Several different treatment modalities are currently used in
AML, including intensive chemotherapy (induction, consoli-
dation, maintenance or palliative), treatment with
hypomethylating agents (i.e. Azacytidine), haematopoietic
stem cell transplantation (HSCT) and best supportive care.
Age, gene mutations and cytogenetics of the leukaemic clone
are known to drive leukemogenesis and are important prog-
nostic factors. To date, approximately 30 gene mutations have
been identified affecting prognosis in AML, the most impor-
tant being: FMS-l ike tyros ine kinase 3 (FLT3) ,
nucleophosmin 1 (NPM1), DNA methyltransferase 3A
(DNMT3A), tumour protein 53 (TP53), TET methylcytosine
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dioxygenase 2 (TET2) and isocitrate dehydrogenase (IDH1/2)
[3].
Leukemogenesis
The bone marrow is a viscous tissue within the bone, which is
primarily responsible for haematopoiesis. The concept of the
specialised niches was originally described in 1978 by
Schofield [4]. Two main anatomical BM niches have been
described: the vascular and the endosteal niches, which are
closely related and work collaboratively [5]. The interactions
include several cytokines, the extracellular matrix, adhesion
factors, which affect colonization, differentiation, and homing
of haematopoetic stem cells (HSCs) [6]. The endosteum is
located close to trabecular or cortical bone and is lined by
osteoblasts (OB) and osteoclasts (OC). The perivascular niche
is located close to sinusoids and arterioles, including the sur-
rounding supportive stromal cells and extracellular matrix
(ECM) [7, 8]. In reality, the BMmicroenvironment is dynamic
and separation of the two BM niches is difficult, as HSCs
interact with numerous structures and through several signal-
ling axes simultaneously [8].
Haematopoietic stem cells are primitive multipotent stem
cells initially formed during embryogenesis. They then move
to foetal spleen and liver, and finally migrate to the BM, where
they reside in separate specialised niches. The HSCs remain in
the BM until maturation, where they interact with other sur-
rounding supporting cells such as sympathetic neurons, extra-
cellular matrix, arteriolar and sinusoidal endothelial cells and
BM stromal cells (also known as mesenchymal stem cells
(MSC)), which can differentiate into osteoblasts,
chondrocytes, fibroblasts and adipocytes [9]. The interaction
between the niche and HSC regulates their function and prop-
erties such as proliferation, differentiation, localization and
self-renewal. During normal myelopoiesis, HSCs differentiate
into mature blood cells via progenitor populations, of which
there are mainly two lineages: the common lymphoid progen-
itor (CLP) and the common myeloid progenitor (CMP).
During the early stages of myeloid malignancies, the HSCs
may accumulate genetic mutations that transform them into
leukaemic stem cells (LSCs). The LSCs can then remodel the
niche into a favourable environment for expansion or can even
induce leukaemic transformation. Alternatively, mutations
may occur in the progenitor populations such as lymphoid-
primed multipotent progenitors (LMP) and granulocyte mac-
rophage progenitors (GMP) [10]. Later in the disease, the
LSCs become independent of the BM signals and localize
more centrally. The stromal cells acquire an abnormal pheno-
type, and angiogenesis increases [11]. The aim of chemother-
apy is to eradicate the LSC population, but at the same time, it
damages the other cells of the niche, triggering regeneration.
Prolonged treatment induces the development of resistance
mechanisms, some of which are mediated by stromal or en-
dothelial cells and results in LSCs which persist after chemo-
therapy and mediate disease relapse [11].
InteractionsWithin the BMMicroenvironment
The mechanism of stroma-mediated protection of leukaemic
cells is complex and involves several cytokines, chemokines
and adhesion molecules produced by the surrounding BM
non-haemopoietic cells. The AML cells, their neighbouring
stromal cells, normal haematopoietic cells as well as the infil-
trating immunocompetent cells in the bone marrow produce
survival and growth-regulatory chemokines and express a
wide range of chemokine receptors. There are two major che-
mokine subclasses, CCL and CXCL chemokines, which in-
teract with CCR and CXCRmembrane receptors, respectively
[12]. Several cytokines, chemokines and other soluble factors
have been implicated in the AML-BM niche bidirectional
crosstalk including CXCR2, CXCR4, IL6R, LFA, VLA4,
RANK and FAT/CD36 [9]. A few of the interactions are sum-
marized in the figure below (Fig. 1).
Bruserud et al. proposed a classification system of AML
patients into distinct subsets according to their chemokine
responsiveness and chemokine release profile. Three chemo-
kine release groups were identified by the cluster and principal
component analyses using 68 AML patients and 22
chemokines: (i) CCL2-4/CXCL1/8, (ii) CCL5/CXCL9-11,
and (iii) CCL13/17/22/24/CXCL5. AML cells from patients
without detectable chemokines were shown to have decreased
chemotaxis. No correlations were found between any patient
cluster and cytogenetic abnormalities [12].
Endothelial Cells
Endothelial cells are located within the BM sinusoid. Their
main function is to regulate the migration of cells between the
BM and circulation by providing a vascular network [13].
Leukaemic cells secrete cytokines, in particular TNF-alpha
and IL-1 beta, which in combination with the direct contact
between adhesion receptors activate endothelial cells. As a
result, leukaemic cells appear to promote their own adhesion
to vascular endothelium [14]. The main pathways through
which myeloblasts adhere to human endothelial cells are via
E-selectin, vascular cell adhesion molecule-1 (VCAM-1) [15]
as well as P-selectin. HSCs express P-selectin glycoprotein
ligand-1 (or CD162), CD44 and E-selectin receptors as well
as Very late antigen 4 (VLA-4), which is anα4β1 integrin that
facilitates the adhesion of AML cells to VCAM-1 and fibro-
nectin [9]. Other receptors for VCAM-1 are α4β717 and
α9β1, which have also been shown to be involved in the
interaction between HSC and the BM niche [16]. P- and E-
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selectin mediate the initial rolling of HSC on the endothelium
and once slowed, HSC can then adhere via integrins and mi-
grate to BM stroma through the endothelium [16]. Hyaluronic
acid (HA) is the major ligand of CD44 and comprises an
important component of the ECM in many organs, including
the BM, where it is produced by endothelial, stromal and
haematopoietic cells [17]. Ellis et al. showed that transplanted
HSC home preferentially to the trabecular-rich metaphysis of
the femurs, where they exist in close association with blood
vessel endothelial cells that express high levels of HA. This
confirms that HA is fundamental for the homing of HSCs to
the metaphysis [18]. The interactions between AML and
Fig. 1 aComponents and structure of the haematopoietic niche. b Summary of interactions between AML cells and the bonemarrowmicroenvironment
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endothelial cells promote angiogenesis through the Notch/
Dll4 pathway [19]. The proangiogenic factor vascular endo-
thelial growth factor (VEGF) was found to be high in AML
patients leading to angiogenesis and decreased rate of apopto-
sis. Finally, culturing endothelial cells with VEGF induced an
increase of granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) secretion by endothelial cells, which is known
to stimulate growth in AML cells [20].
Fibroblasts
Fibroblasts are important in the survival and migration of
leukaemic cells. Runingen et al. cultured primary AML blasts
with normal human BM stromal cells and two fibroblast lines
separated by a semipermeable membrane, which resulted in
enhanced proliferation, antiapoptotic signalling and increased
levels of proangiogenic IL8 [21]. Zhai et al. demonstrated that
there are several functional cancer-associated fibroblasts
(CAFs) within the BM of AML patients. These produce
growth differentiation factor 15 (GDF15), which protects the
AML cells from chemotherapy [22].
Osteoclasts and Osteoblasts
The endosteum is lined by osteoblasts and osteoclasts, which
regulate bone formation and resorption and form an important
part of the bone marrow microenvironment. Multiple myelo-
ma cells adhere on BM stromal cells, which induce osteoclas-
togenesis [23]. The main pathways involved in increased os-
teoclast formation in multiple myeloma are osteoprotegerin
(OPG), macrophage inflammatory protein (MIP)-1α, IL-6,
IL-3 and RANK ligand (RANKL). The RANK/RANKL path-
way is critical for bone remodelling. RANK is a TNF receptor
found on the surface of osteoclasts, and its ligand RANKL is a
membrane-bound protein found on stromal cells and osteo-
blasts, and is also secreted by activated lymphocytes. Their
binding induces osteoclastogenesis and increases osteoclast
survival [24]. RANK is also expressed on natural killer
(NK) cells. RANKL is expressed in AML patient cells and
the factors elicited by RANK/RANKL signalling induce
RANK on NK cells and impair their antileukaemic activity
[25]. The endosteal surface is high in calcium ion concentra-
tion, which attracts and retains HSC through their calcium-
sensing receptor (CaR) in vivo [26].
Osteoblasts form an interface between the marrow and the
bone and can be divided into two types: spindle-shaped N-
cadherin + osteoblasts (SNO) and oval-shaped osteoblasts
[27]. Battula et al. showed that AML cells induce osteogenic
differentiation in MSC to support leukemogenesis. In fact,
AML cells were shown to promote osteoblastic and inhibit
adipogenic differentiation of MSCs, suggesting that a AML
cells enhance their expansion by inducing a preosteoblast-rich
niche in the BM [28•]. Using an immunocompetent in vivo
model of AML, Frisch et al. showed that leukaemia decreases
osteoblasts and induces bone loss via reduced levels of
osteocalcin [29]. Osteopontin is an extracellular matrix protein
produced by osteoblasts and osteoclasts, which has been
shown to mediate HSC localization to the endosteal niche.
Osteoblasts were shown to regulate the HSC niche through
Notch 1 activation on HSC, which increased their expansion
in vivo [30]. Zhang et al. confirmed this finding using a dif-
ferent model of mutant mice, where increased osteoblasts led
to increased HSC number. BMP signalling was shown to con-
trol the number of HSCs by regulating niche size [27]. The
expression of tyrosine kinase Tie2 receptor on HSC was as-
sociated with quiescent HSCs, and its interaction with its li-
gand angiopoietin-1 (Ang-1) enhanced adhesion to osteo-
blasts through activation of β1-integrin and N-cadherin [31].
Published literature suggests that loss of CXCL12 expression
by osteoblast is a key step in cytokine-induced HSC mobili-
zation [32]. The CXCL12/CXCR4 axis is fundamental for the
HSC and LSC interaction with the BMmicroenvironment and
will be discussed in detail below.
Adipocytes
Adipose tissue, in particular its stromal vascular fraction
(SVF), was shown to act as an extramedullary reservoir for
haematopoietic stem and progenitor cells [33]. In adult
humans, the adipose tissue accounts for up to 70% of the bone
marrow. The role of adipocytes remains controversial.
Adipocytes were implicated as predominantly negative regu-
lators of the BMmicro-environment, and inhibiting adipogen-
esis may enhance haematopoietic recovery in BM transplan-
tation [34]. Boyd et al. showed that AML cells disrupt endog-
enous myelo-erythropoiesis by compromising the adipocytic
niche [35•].
In contrast, Tabe et al. showed that the interaction between
acute monocytic leukaemia cells and adipocytes prevented
their apoptosis through an increase in fatty acid β-oxidation
(FAO) and upregulation of PPARγ, FABP4, CD36 and BCL2
genes. The co-culture increased adiponectin receptor gene ex-
pression and its downstream target stress response kinase
AMPK. Pharmacological inhibition of FAO induced the inte-
grated stress response mediator ATF4 and apoptosis in mono-
cytic cells, suggesting that disruption of FAO in bone marrow
adipocytes may be a potential therapeutic strategy for AML
therapy [36]. Lee et al. performed a high-throughput screen
and identified avocatin B, a FAO inhibitor, as a novel com-
pound with cytotoxic activity in AML [37]. Ye et al. used a
mouse model of blast crisis chronic myeloid leukaemia
(CML), where adipose-resident CD36+ LSCs had increased
FAO. CD36(+) LSCs and were protected from [38]. Lastly,
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Shafat et al. showed that BM adipocytes support the survival
and proliferation of AML cells in vivo and in vitro. The AML
blasts induce phosphorylation of lipase in adipocytes, which
consequently activates lipolysis. Co-culturing AML cells with
adipocytes upregulates the fatty acid-binding protein-4
(FABP4) messenger RNA. Knockdown of FABP4 reversed
the AML cell protection from adipocytes [39].
Sympathetic Neural Cells
Recent evidence showed that CD34+ cells also expressed
beta2-adrenergic and dopamine receptors. G-CSF-treatment
upregulated the neuronal receptor expression on CD34+ cells.
Finally, adrenaline and noradrenaline regulated CD34+ cell
motility and proliferation, in vitro as well as in vivo [40].
Patients with myeloproliferative neoplasms have reduced
sympathetic nerve fibres, supporting Schwann cells and
Nestin+ MSCs in the bone marrow, mainly due to bone mar-
row neural damage by interleukin-1β, which is produced by
mutant HSCs and favours their expansion. Treatment withβ3-
adrenergic agonists prevented the loss of Nestin+ MSCs and
blocked MPN progression [41]. The sympathetic nervous sys-
tem (SNS) was shown to promote leukaemic bone marrow
infiltration in an MLL-AF9 AML model. AML disrupts
SNS nerves and the quiescence of Nestin+ niche cells, leading
to an expansion of altered mesenchymal stem and progenitor
cells at the expense of HSC-maintaining niche cells [42]. Non-
myelinating Schwann cells activate latent TGF-β, which af-
fects HSC maintenance and repopulating activity. Autonomic
nerve denervation resulted in rapid loss of HSCs from BM, by
reducing the number TGF-β-producing cells [43].
T Cells
T cells are known to be a crucial part of the immune system’s
defence against malignancy; however, there is increasing ev-
idence to show that Tcells can be dysregulated in the presence
of AML, and their actions can be subverted to a more
immune-suppressed state [44]. Here, the effects on the
CD8+ cytotoxic cells and multiple subsets of the CD4+ Tcells
are considered. These mechanisms are important, as T cells
have been implicated in the development of treatments for
AML, for example creating chimeric T cells specifically
targeting the tumour, and that T cells have a role in the success
of current treatments such as stem cell transplantation
[44–47]. T cells require co-stimulatory molecules during acti-
vation, and this can be counteracted by upregulation of inhib-
itory molecules, such as programmed cell death (PD-1),
CD244, CD160 and T cell immunoglobulin and mucin- do-
main containing-3 (TIM-3) [44].
Jia found that CD8+ T cells in the bone marrow of AML
patients were more terminally differentiated, expressing more
factors associated with exhaustion and had reduced function
(in killing capacity and cytokine production) compared to
those in the peripheral blood [48]. They also found higher
levels of PD-1 expression in the CD8+ T cells in the bone
marrow.
Zhang found that the PD-1 ligand was upregulated on the
tumour cells in a murine leukaemia model in vivo. When PD-
1 was knocked down, or the mice were given an inhibitory
antibody, they had a reduced tumour burden and a larger
antileukaemic response [49]. TIM-3, another inhibitory recep-
tor, has also been implicated in T cell exhaustion [50] and is
found at higher levels on marrow resident T cells. It was also
found that expression of TIM-3 and its partner, Gal-9
(expressed on AML cells), was significantly in higher in pa-
tients with treatment failure [51]. In contrast, a review by
Lamble et al. discussed the concept of T cell exhaustion and
reduced functionality and reported that there is still contradic-
tory evidence surrounding whether it occurs in AML, perhaps
due to the high heterogeneity of the disease [44]. For example,
Schnorfeil et al. found that while PD-1 was upregulated after
relapse, they did not find that this was associated with a func-
tional deficit in the T cells. These tests were performed in
peripheral blood [52]. This highlights the need for further,
larger studies involving more patients to establish the full
mechanism, as immune checkpoints are a potential therapeutic
target.
Aside from expression of ligands and receptors, there is
accumulating evidence for the involvement of secreted fac-
tors. Buggins et al. showed that without physical contact,
AML cells could produce a protein which lead to blockade
of activation of Th1 cells and their cytokine production, and
inhibited activated T cells from entering the cell cycle [53].
Milojkovic showed that this tumour-derived supernatant
inhibited apoptosis of both AML and the other haematopoietic
stem cells [54]. It has been shown that low arginine levels are
associated with T cell exhaustion, and that supplementation
reverses this. An enzyme called arginase II, expressed by
AML cells, has been implicated [55]. Secretion of galectins
[56] and production of reactive oxygen species [57] have also
been linked to the AML microenvironment and immune
suppression.
In contrast to the potential reduced function of some Tcells
in the AMLmicroenvironment, T-regulatory (T-reg) cells are a
subclass of T cells which are involved in self-tolerance [44].
They have been found to work in conjunction with AML by
creating a localized zone where HSPC can reside on the end-
osteal surface and improve their survival [58]. Studies have
shown accumulation of Tregs in the bone marrow in AML
[59]. Han et al. showed that AML can express a Treg co-
stimulatory ligand ICOS-L, activating Tregs directly, and they
can also induce some CD4+ cells to become inducible Tregs.
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These ICOS+ T cells can then produce IL-10 which encour-
ages the proliferation of AML in turn [59] and were shown to
have an inhibitory action on T effector cells.
Aside from the traditional Th1/Th2 axis, a review by Li
et al. concluded that there was evidence of Th17 dysregulation
in AML, both in Th17 cells, and in the production of Th17-
associated cytokines [60]. More recent papers have concluded
similar results, for example Han et al. showed an increase in
Th17 cells in peripheral blood, and in the bone marrow in
AML compared to healthy controls, and an increase in their
associated cytokines [61]. They also found a lower frequency
of Th1 cells. Higher levels of Th17 and lower Th1 were asso-
ciated with a poorer prognosis.Wróbel also found in 2014 that
a particular IL-17 polymorphism was associated with an in-
creased susceptibility to AML [62].
In summary, there is evidence of dysregulation of all sub-
sets of T cells in the AML microenvironment, and it appears
that AMLmay have a role in enabling this dysregulation. This
involves both expression of both cell-bound and secreted mol-
ecules. Given T cells are one of the crucial mechanisms for
many AML treatments, further investigation and expansion
from murine models may yield further insight.
Mesenchymal Cells and CXCL12-Abundant
Reticular Cells
Mesenchymal stem cells (or stromal cells) can be identified by
the expression of Nestin, LepR, Prx-1 or Mx-1 [5]. The
perivascular niches include CXCL12-abundant reticular
(CAR) cells, Nestin-positive (Nestin+) MSCs and leptin
receptor-positive (LepR+) MSCs. Nestin+ MSCs, which usu-
ally co-localize with adrenergic nerve fibres, can affect HSC
homing to the BM [63]. Stem cell factor (SCF) conditional
deletion from LepR+ stromal cells reduced HSC number in the
BM [64]. During haematopoiesis, the HSC are retained in
cellular niches, which are created by stromal cells in order to
grow and differentiate [65]. Co-culturing stromal cells with
AML blasts was shown to inhibit cytotoxic drug-induced ap-
optosis via soluble factors as well as cell contact-mediated
pathways [66]. Direct contact of AML cells with HS5 (a hu-
man stromal cell line) can significantly increase their prolifer-
ation, viability and colony formation [67]. When AML cells
were cultured on patient-derived multipotent MSCs, their pro-
liferation capacity was shown to be significantly higher com-
pared to when they were cultured onMS5 (mouse stromal cell
line) or liquid culture [68••]. Abdul-Aziz et al. investigated the
cytokine profile of AML cells cultured in a co-culture system
using bone marrow mesenchymal cells. It was shown that
macrophage migration inhibitory factor (MIF) was highly
expressed by primary AML, and that IL8 was increased in
the co-cultures, promoting AML survival [69]. Co-culturing
primary human AML cells with normal BM mesenchymal
stem cells (MSCs) supported their proliferation and survival
in vitro through the release of soluble mediators. This effect
was independent of cytogenetic abnormalities [70••].
Studies on the chemokine CXCL12 (also known as stromal
derived factor-1 (SDF-1)) revealed that it is highly expressed
in a population of reticular cells, the CXCL12 expressing re-
ticular (CAR) cells. They are scattered throughout the bone
marrow, creating a network in the perivascular region of BM,
either surrounding the sinusoidal endothelial cells or located
near the endosteum. CAR cells are progenitors of mesenchy-
mal stromal cells and can differentiate into osteoblasts or ad-
ipocytes. These cells have a fundamental role in maintaining
of the HSC in bone marrow stromal cell niches [71]. Early B
cell factor (Ebf3) is secreted from leptin receptor expressing-
CAR cells, which subsequently regulates the interplay be-
tween osteogenesis and haematopoiesis [72]. Their differenti-
ating capacity as well as their ability to release high levels of
CXCL12 make these cells potential candidates for targeting.
CXCL12 and its receptor (CXCR4) have been implicated as
critical mediators of the stromal-leukaemic cell interaction,
affecting AML cell survival [73], migration [74], adhesion
[9, 75] and disease progression by acting as a survival factor
for both normal and leukaemic haematopoietic cells.
Leukaemic cells use CXCL12/CXCR4 axis to access the pro-
tective BM niches, which usually tend to be restricted to nor-
mal HSCs. As a result, they reside in a safe environment that
promotes their survival and protects them from chemotherapy
[6]. Inhibiting the axis can interrupt this communication and
induce AML cell mobilization away from the protective
niches, where they can be targeted by chemotherapy. Lastly,
CXCR4 expression on AML cells has been shown to adverse-
ly affect patient survival [76].
Conclusion
There is a definite clinical need to improve treatment in AML,
which remains to be a rapidly progressing leukaemia with
poor prognosis and high relapse rate. The BM microenviron-
ment interacts with normal HSC and leukaemic cells in sev-
eral ways affecting their cellular functions, including their
proliferation, differentiation, adhesion, quiescence, trafficking
and clonal expansion [77]. The mechanism of stromal-
mediated protection of leukaemic cells and their anchorage
in the BM is complex and involves many cytokines,
chemokines and adhesion molecules. Interactions between
the leukaemic cells and other cells in the BM microenviron-
ment are known to be vital for the maintenance and progres-
sion of chemotherapy-resistant AML [78], where blasts are
thought to remodel the BM niche, favouring leukaemia
growth and suppressing normal haematopoiesis through
exosome secretion [79••]. As a result, the BM is considered
to provide a primary site for minimal residual disease, which
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causes relapse after chemotherapy and is critical in mediating
drug resistance. Given the AML dependence on the BM mi-
croenvironment, a better understanding of the biology and
interactions between the leukaemic cells and the
haematopoietic niche is needed, in order to develop therapies
that co-target several signalling pathways simultaneously.
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